Regeneron Pharmaceuticals
REGN
$744.44
-0.95%
Regeneron Pharmaceuticals is a leading biotechnology company that discovers, develops, and commercializes therapies for serious medical conditions including eye diseases, cardiovascular disease, cancer, and inflammation. The company is a major player in immunology and ophthalmology, distinguished by its robust antibody platform and key marketed products like Eylea, Dupixent, and Libtayo. The current investor narrative is dominated by the blockbuster growth trajectory of Dupixent, recent regulatory expansions for its use, and strategic maneuvers to navigate a shifting U.S. drug pricing landscape, including a notable deal with the Trump administration for policy certainty in exchange for potential future price concessions.…
REGN
Regeneron Pharmaceuticals
$744.44
Related headlines
REGN 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Regeneron Pharmaceuticals's 12-month outlook, with a consensus price target around $967.77 and implied upside of +30.0% versus the current price.
Average Target
$967.77
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$596 - $968
Analyst target range
Regeneron is covered by 11 analysts, and the institutional ratings show a mix of 'Buy/Overweight/Outperform' and 'Hold/Equal-Weight' recommendations, indicating a generally bullish but cautiously optimistic consensus sentiment. The average analyst revenue estimate for the upcoming period is $21.44 billion, with a high estimate of $23.43 billion and a low of $19.62 billion, reflecting a range of outcomes primarily tied to the commercial performance of Dupixent and the erosion or stability of Eylea sales. The wide spread between the high and low revenue estimates signals meaningful uncertainty and debate among analysts regarding the company's near-term growth trajectory and margin profile, likely influenced by drug pricing negotiations and competitive dynamics.
Bulls vs Bears: REGN Investment Factors
The investment debate for Regeneron centers on the tension between its powerful, cash-generative blockbuster franchise and emerging pressures on growth and margins. The bull case is stronger, anchored in Dupixent's expansion, exceptional profitability, a valuation discount to history, and a strategic move to secure policy certainty. However, significant bearish evidence exists, primarily the sharp deceleration in revenue growth and the explicit long-term margin pressure from the recent pricing deal. The single most important tension is whether Dupixent's growth can accelerate sufficiently to offset Eylea headwinds and pricing concessions, thereby re-igniting top-line growth and justifying a higher valuation multiple. The resolution of this growth trajectory will be the primary driver of the stock's performance over the next 12 months.
Bullish
- Strong Dupixent Growth & FDA Expansions: Recent FDA approvals have broadened the label for blockbuster drug Dupixent, a key growth driver. This expansion, combined with a strong earnings beat from partner Sanofi, signals robust commercial momentum and potential for sustained revenue growth above the modest 2.5% YoY rate seen in Q4 2025.
- Exceptional Profitability & Cash Generation: The company maintains industry-leading gross margins of 84.95% and generated $4.08 billion in TTM free cash flow. This strong profitability and cash generation provide ample internal funding for R&D and strategic initiatives without reliance on debt, as evidenced by a low debt-to-equity ratio of 0.087.
- Valuation Discount to Recent History: The stock trades at a trailing P/E of 17.92x, which is below its own Q4 2025 historical ratio of 23.51x and significantly below peaks above 36x seen in early 2024. This discount to its own recent valuation suggests a potential value opportunity if growth re-accelerates or concerns over drug pricing ease.
- Defensive Profile with Low Beta: With a beta of 0.397, REGN is approximately 60% less volatile than the broader market. This defensive characteristic reduces portfolio risk and makes the stock behave more like a large-cap healthcare staple, which is attractive in uncertain market environments, as shown by its 25.3% 1-year gain despite recent market volatility.
Bearish
- Decelerating Revenue Growth: Q4 2025 revenue grew only 2.5% year-over-year, a significant slowdown from stronger growth in prior quarters. This deceleration raises questions about the near-term growth trajectory, especially if it reflects pressure on legacy products like Eylea not being fully offset by Dupixent's expansion.
- Quarterly Profitability Volatility: Q4 2025 net income of $844.6 million and gross margin of 84.95% were down from Q3's $1.46 billion and 86.11%, indicating significant earnings volatility. This compression could signal margin pressure from the drug pricing deal or investment timing, creating uncertainty for quarterly results.
- Analyst Revenue Estimate Uncertainty: Analyst revenue estimates for the upcoming period range widely from $19.62B to $23.43B, with an average of $21.44B. This wide spread reflects meaningful debate and uncertainty regarding the company's near-term growth, likely tied to drug pricing negotiations and competitive dynamics.
- Technical Momentum Stalling Near Highs: The stock is trading at 80% of its 52-week range, close to its high of $821.11, but recent momentum has stalled with a 0.28% 1-month gain and a -0.26% 3-month decline. This suggests potential for near-term consolidation or a pullback after a powerful 30% six-month surge.
REGN Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 25.31% 1-year price change. With a current price of $751.57, it is trading at approximately 80% of its 52-week range ($476.49 to $821.11), positioning it closer to recent highs which suggests strong momentum but also potential for near-term consolidation or overextension after a significant run. Recent momentum shows signs of stalling, with a modest 0.28% gain over the past month and a slight 0.26% decline over the past three months, indicating a deceleration from the powerful 30.04% six-month surge and potential short-term consolidation within the broader uptrend. Key technical support is anchored near the 52-week low of $476.49, while immediate resistance is at the 52-week high of $821.11; a decisive breakout above resistance would signal a resumption of the primary bull trend, while a breakdown below the recent trading range could indicate a deeper correction. The stock's beta of 0.397 indicates it is approximately 60% less volatile than the broader market (SPY), which is unusually low for a biotech and suggests it has traded more like a defensive, large-cap healthcare stock, reducing portfolio risk but also limiting explosive upside relative to the sector.
Beta
0.40
0.40x market volatility
Max Drawdown
-26.9%
Largest decline past year
52-Week Range
$476-$821
Price range past year
Annual Return
+23.5%
Cumulative gain past year
| Period | REGN Return | S&P 500 |
|---|---|---|
| 1m | +0.9% | +12.8% |
| 3m | -3.5% | +2.8% |
| 6m | +14.0% | +4.0% |
| 1y | +23.5% | +29.9% |
| ytd | -4.1% | +4.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
REGN Fundamental Analysis
Revenue growth remains positive but has decelerated, with Q4 2025 revenue of $3.88 billion representing a modest 2.5% year-over-year increase, a slowdown from the stronger growth seen in prior quarters of 2025. Segment data shows Collaboration Revenue ($1.97B) and Product Revenue ($1.67B) as the primary drivers, though the product mix and growth rates for key drugs like Dupixent versus Eylea are critical for the trajectory. The company is highly profitable, posting Q4 2025 net income of $844.6 million and an industry-leading gross margin of 84.95%; however, profitability was compressed in Q4 compared to Q3's net income of $1.46 billion and gross margin of 86.11%, indicating some quarterly volatility in earnings, potentially due to investment timing or revenue mix. The balance sheet is exceptionally strong with a low debt-to-equity ratio of 0.087 and a robust current ratio of 4.13, while the company generated substantial trailing twelve-month free cash flow of $4.08 billion, providing ample internal funding for R&D, share buybacks, and strategic initiatives without reliance on external financing.
Quarterly Revenue
$3.9B
2025-12
Revenue YoY Growth
+0.02%
YoY Comparison
Gross Margin
+0.84%
Latest Quarter
Free Cash Flow
$4.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is REGN Overvalued?
Given the company's consistent profitability (Net Income > 0), the primary valuation metric is the Price-to-Earnings (PE) ratio. Regeneron trades at a trailing PE of 17.92x and a forward PE of 14.24x; the lower forward multiple suggests the market expects earnings growth, likely driven by continued Dupixent expansion and pipeline advancements. Compared to typical biotechnology industry averages, a trailing PE in the high-teens to low-20s is generally in line or at a slight premium; the current multiple does not suggest extreme overvaluation relative to the sector, especially given the company's profitability and growth profile. Historically, the stock's own trailing PE has ranged widely; the current 17.92x is below the Q4 2025 historical ratio of 23.51x and significantly below peaks seen in 2024 (e.g., 36.18x in Q1 2024), indicating the stock is trading at a discount to its own recent historical valuation, which could reflect market concerns over pricing pressures or represent a value opportunity if growth re-accelerates.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 5x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Regeneron's primary financial risk is the deceleration of revenue growth to just 2.5% YoY in Q4 2025, which raises concerns about dependence on Dupixent to offset potential declines in mature products like Eylea. While profitability is high, quarterly volatility is a concern, with Q4 net income dropping 42% sequentially from Q3. Furthermore, the recent deal with the Trump administration explicitly introduces long-term margin pressure through future price concessions and free product giveaways, directly threatening the company's premium 85% gross margin. The wide range in analyst revenue estimates ($19.6B to $23.4B) underscores the uncertainty in the near-term financial trajectory.
Market & Competitive Risks: The stock trades at a forward P/E of 14.24x, which is reasonable for a profitable biotech but does not price in explosive growth, leaving limited room for multiple expansion. Competitive risks are material, as seen in news of AstraZeneca's successful Phase 3 trial for a COPD drug, which could challenge Dupixent in key markets. The broader U.S. drug pricing landscape remains a persistent threat, with the company's recent deal being a proactive but costly mitigation. REGN's low beta of 0.397 suggests it is less sensitive to market swings, but this also means it may not participate fully in market rallies, as evidenced by its -5.3% relative strength versus the SPY over the past year.
Worst-Case Scenario: The worst-case scenario involves a perfect storm where Dupixent growth fails to accelerate, Eylea sales erode faster than expected, and the drug pricing deal leads to deeper-than-anticipated margin compression. This could trigger analyst downgrades and a de-rating of the stock towards its 52-week low of $476.49. Given the current price of $751.57, this scenario implies a potential downside of approximately -37%. A more realistic severe bear case, aligning with the lower end of analyst uncertainty, could see the stock fall 20-25% if quarterly earnings consistently disappoint and growth stalls in the mid-single digits.